ABBV

SEC source: 0001415889-25-004462 · form4-02182025_050216.xml · nonDerivative · entry 2

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,892

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004462 · form4-02182025_050216.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,052

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004463 · form4-02182025_050218.xml · derivative · entry 5

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028.

SEC source: 0001415889-25-004463 · form4-02182025_050218.xml · nonDerivative · entry 4

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,954

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004463 · form4-02182025_050218.xml · nonDerivative · entry 3

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,606

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004463 · form4-02182025_050218.xml · nonDerivative · entry 2

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,468

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004463 · form4-02182025_050218.xml · nonDerivative · entry 1

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,994

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004464 · form4-02182025_050220.xml · derivative · entry 5

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires 2035-02-12

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,084 on February 13, 2026, 2,083 on February 13, 2027, and 2,083 on February 13, 2028.

F5 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,084 on February 13, 2026, 2,083 on February 13, 2027, and 2,083 on February 13, 2028.

SEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 4

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,330

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 3

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,656

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 2

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,052

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-004464 · form4-02182025_050220.xml · nonDerivative · entry 1

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,578

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.

SEC source: 0001415889-25-000519 · form4-01032025_050103.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401

Underlying: Common Stock · 84 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-000520 · form4-01032025_050105.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,976

Underlying: Common Stock · 182 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-000521 · form4-01032025_050107.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,788

Underlying: Common Stock · 42 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-029754 · form4-12182024_051202.xml · derivative · entry 3

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,111

Underlying: Common Stock · 1,800 shares

Expires 2030-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-24-029754 · form4-12182024_051202.xml · nonDerivative · entry 2

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,983

SEC source: 0001415889-24-029754 · form4-12182024_051202.xml · nonDerivative · entry 1

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-024450 · form4-10022024_051002.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 314

Underlying: Common Stock · 75 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-024451 · form4-10022024_051005.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 388,929

SEC source: 0001415889-24-024451 · form4-10022024_051005.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 425,627

SEC source: 0001415889-24-024451 · form4-10022024_051005.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 441,356

SEC source: 0001415889-24-024452 · form4-10022024_051007.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,655

Underlying: Common Stock · 37 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-024453 · form4-10022024_051010.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,544

Underlying: Common Stock · 164 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-024096 · form4-09302024_090946.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,348

SEC source: 0001415889-24-020926 · form4-08072024_050802.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 446,599

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.50 to $186.90 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000897069-24-001526 · form4.xml · derivative · entry 7

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,755

Underlying: Common Stock · 76,377 shares

Expires 2030-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0000897069-24-001526 · form4.xml · derivative · entry 6

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,709

Underlying: Common Stock · 119,418 shares

Expires 2029-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0000897069-24-001526 · form4.xml · derivative · entry 5

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 87,050 shares

Expires 2027-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 4

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 513,099

SEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 795,944

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 719,567

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000897069-24-001526 · form4.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · EXECUTIVE CHAIRMAN OF BOARD

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 600,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000897069-24-001471 · form4.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,541

Underlying: Common Stock · 43 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0000897069-24-001473 · form4.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,170

Underlying: Common Stock · 225 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0000897069-24-001475 · form4.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236

Underlying: Common Stock · 87 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0000897069-24-001469 · form4.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 513,099

SEC source: 0001415889-24-012519 · form4-05072024_060504.xml · nonDerivative · entry 1

WADDELL FREDERICK H · CIK 0001223690 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,755

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012520 · form4-05072024_060507.xml · nonDerivative · entry 1

TILTON GLENN F · CIK 0001194624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,361

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012521 · form4-05072024_060509.xml · nonDerivative · entry 1

Roberts Rebecca B · CIK 0001355580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,525

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012523 · form4-05072024_060513.xml · nonDerivative · entry 1

Hart Brett J · CIK 0001466338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,269

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012522 · form4-05072024_060511.xml · nonDerivative · entry 1

MEYER MELODY B · CIK 0001706126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,295

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012524 · form4-05072024_060515.xml · nonDerivative · entry 1

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,548

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012525 · form4-05072024_060517.xml · nonDerivative · entry 1

BURNSIDE WILLIAM H.L. · CIK 0001563579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,755

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012526 · form4-05072024_060519.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,255

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012527 · form4-05072024_060528.xml · nonDerivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,443

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012528 · form4-05072024_100531.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,356

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012530 · form4-05072024_100540.xml · nonDerivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,322

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-012558 · form4-05082024_120518.xml · nonDerivative · entry 1

Davis Jennifer L. · CIK 0001916665 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,322

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-24-009800 · form4-04022024_050401.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147

Underlying: Common Stock · 82 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.